Overview

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR mutation
Phase:
Phase 3
Details
Lead Sponsor:
Beta Pharma, Inc.
Treatments:
Gefitinib